Indication
Ibandronic acid Sandoz is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.
Loading your page…
Loading your page…
Breast Neoplasms;Neoplasm Metastasis;Fractures, Bone
Marketing Authorisation Holder: Sandoz GmbH
EMA Authorisation: 26/07/2011
INN: ibandronic acid
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ibandronic Acid Sandoz: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.